Docetaxel injection and Capecitabine tablets combined with Oxaliplatin injection in postoperative chemotherapy for esophageal cancer_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

DOU Yawei ¹ , LV Shanshan ² ,  TIAN Wei ¹ , WANG Hongtao ¹ , ZHU Jianfei ¹ , DAI Yun ¹ , LUO Xianghui ¹

1. Department of Thoracic Surgery, Shaanxi People's Hospital, Xi’an, 710068, P.R.China;
2. Department of Cardiothoracic Surgery, Xijing Hospital, The Fourth Military Medical University, Xi’an, 710032, P.R.China;

Corresponding?author：

TIAN Wei, Email: 2108013338@qq.com

Keywords：

Docetaxel; Capecitabine; Oxaliplatin; esophageal cancer

DOI：

10.7507/1007-4848.201607033

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the efficacy of Docetaxel injection and Capecitabine tablets combined with Oxaliplatin injection in chemotherapy for patients after esophageal cancer surgery. Methods We retrospectively analyzed the clinical data of 101 patients with esophageal cancer who underwent radical surgery from June 2010 to December 2012, including 58 males and 43 females. According to the different treatment methods they were divided into a study group (58 patients, 32 males and 26 females, postoperatively receiving Docetaxel injection, Capecitabine tablets, Oxaliplatin injection and chemotherapy) and a control group (43 patients, 26 males and 17 females, taking Docetaxel injection and Capecitabine tablets for 4 consecutive courses). We compared the difference in the outcomes between the two groups. Results There was no significant difference in the level of serum anticancer antigen (CEA), carbohydrate antigen 125 (CA125), carbohydrate antigen 199 (CA199) and squamous cell carcinoma antigen (SCC) before chemotherapy between two groups (P>0.05). After chemotherapy, the level of serum CEA, CA125, CA199, SCC in the study group was significantly lower than that in the control group (P<0.05). The 1-year survival rate of the study group was 92.59% and the 2-year survival rate was 70.37%, which were not significantly different from those of the control group (P>0.05). The 3-year survival rate of the study group was significantly higher than that of the control group (57.41 %vs. 32.43%, P<0.05). The mean survival time of the study group was longer than that of the control group (31 monthsvs. 22 months, P=0.001). Conclusion Docetaxel injection and Capecitabine tablets combined with Oxaliplatin injection for the treatment of esophageal cancer surgery can significantly reduce levels of tumor markers in serum after esophageal cancer surgery, and is favorable for the long-term survival of patients, but adverse reactions should be noted.

Citation： DOU Yawei, LV Shanshan, TIAN Wei, WANG Hongtao, ZHU Jianfei, DAI Yun, LUO Xianghui. Docetaxel injection and Capecitabine tablets combined with Oxaliplatin injection in postoperative chemotherapy for esophageal cancer. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2017, 24(11): 853-857. doi: 10.7507/1007-4848.201607033 Copy

1.	劉建平, 付茂勇, 夏娟, 等. MTA1, VEGF-C 在食管鱗癌中的表達及與淋巴管生成的關系. 中國胸心血管外科臨床雜志, 2016, 23(3): 268-273.
2.	張艷姣, 許翠萍, 喬亞光, 等. CK15 在食管鱗癌患者組織及血清中的表達與意義. 山西醫科大學學報, 2015, 46(8): 793-796.
3.	畢良文, 張麗珍, 趙滑峰, 等. 多西紫杉醇加奈達鉑同期適形調強放療治療食管癌的療效中華腫瘤雜志, 2012, 34(9): 710-711.
4.	泮衛紅, 羅青峰, 陳惠馨, 等. 紫杉醇聯合順鉑治療晚期食管癌 20 例臨床研究.中國醫藥導報, 2010, 7(26): 130-131.
5.	劉沙, 王明坤, 張爽, 等. 多西紫杉醇聯合奈達鉑同步放化療治療局部晚期食管癌臨床觀察.現代中西醫結合雜志, 2015, 24(30): 3351-3353.
6.	劉陽, 趙妍, 袁翎, 等. 食管鱗癌患者預后因素分析.中華腫瘤防治雜志, 2016, 23(2): 91-95.
7.	段星, 趙恩民, 叢鐵川, 等. 頸段食管癌的外科 16 例臨床分析. 臨床耳鼻咽喉頭頸外科雜志, 2013, 27(24): 1347-1350.
8.	龍夢云, 韋詩友, 黃芊, 等. 兩種食管上提徑路對食管癌患者術后并發癥影響的系統評價和 Meta 分析. 中國胸心血管外科臨床雜志, 2015, 22(2): 91-99.
9.	戚艷波, 李高峰, 萬崇華, 等. 基于 QLICP—ES 量表的食管癌患者生命質量影響因素分析.重慶醫學, 2015, 44(35): 4995-4997.
10.	許正年, 胡長路, 胡冰, 等. 食管癌患者化療后感染分析與預后研究. 中華醫院感染學雜志, 2015, 25(21): 4941-4943.
11.	吳志偉, 陳凱, 段衛明, 等. 凋亡抑制蛋白 XIAP 和 Survivin 在晚期胃癌中的表達及其與含多西紫杉醇方案化療療效的相關性.現代腫瘤醫學, 2015, 23(6): 815-820.
12.	劉尚國, 白玉, 趙寶生, 等. 復發轉移食管癌患者的預后因素分析.中華腫瘤雜志, 2015, 37(2): 143-147.
13.	梅靜峰, 秦叔逵, 錢軍, 等. 多西他賽聯合順鉑治療復發性中晚期食管癌賁門癌的臨床研究.臨床腫瘤雜志, 2013, 18(14): 272-273.
14.	葛小林, 孫新臣, 李蘇宜, 等. 低劑量多西紫杉醇對中晚期食管癌放療增敏作用的近期療效觀察.海南醫學, 2011, 19(13): 135-136.
15.	Calpe S, Read M, del Carmen Sancho-Serra M, et al. Abstract C04: In vivo upregulation of bone morphogenic protein 4 (BMP4) in esophageal cancer is through tumor-stroma crosstalk. Cancer Research, 2016, 76(15 Supplement): C04.

1. 劉建平, 付茂勇, 夏娟, 等. MTA1, VEGF-C 在食管鱗癌中的表達及與淋巴管生成的關系. 中國胸心血管外科臨床雜志, 2016, 23(3): 268-273.
2. 張艷姣, 許翠萍, 喬亞光, 等. CK15 在食管鱗癌患者組織及血清中的表達與意義. 山西醫科大學學報, 2015, 46(8): 793-796.
3. 畢良文, 張麗珍, 趙滑峰, 等. 多西紫杉醇加奈達鉑同期適形調強放療治療食管癌的療效中華腫瘤雜志, 2012, 34(9): 710-711.
4. 泮衛紅, 羅青峰, 陳惠馨, 等. 紫杉醇聯合順鉑治療晚期食管癌 20 例臨床研究.中國醫藥導報, 2010, 7(26): 130-131.
5. 劉沙, 王明坤, 張爽, 等. 多西紫杉醇聯合奈達鉑同步放化療治療局部晚期食管癌臨床觀察.現代中西醫結合雜志, 2015, 24(30): 3351-3353.
6. 劉陽, 趙妍, 袁翎, 等. 食管鱗癌患者預后因素分析.中華腫瘤防治雜志, 2016, 23(2): 91-95.
7. 段星, 趙恩民, 叢鐵川, 等. 頸段食管癌的外科 16 例臨床分析. 臨床耳鼻咽喉頭頸外科雜志, 2013, 27(24): 1347-1350.
8. 龍夢云, 韋詩友, 黃芊, 等. 兩種食管上提徑路對食管癌患者術后并發癥影響的系統評價和 Meta 分析. 中國胸心血管外科臨床雜志, 2015, 22(2): 91-99.
9. 戚艷波, 李高峰, 萬崇華, 等. 基于 QLICP—ES 量表的食管癌患者生命質量影響因素分析.重慶醫學, 2015, 44(35): 4995-4997.
10. 許正年, 胡長路, 胡冰, 等. 食管癌患者化療后感染分析與預后研究. 中華醫院感染學雜志, 2015, 25(21): 4941-4943.
11. 吳志偉, 陳凱, 段衛明, 等. 凋亡抑制蛋白 XIAP 和 Survivin 在晚期胃癌中的表達及其與含多西紫杉醇方案化療療效的相關性.現代腫瘤醫學, 2015, 23(6): 815-820.
12. 劉尚國, 白玉, 趙寶生, 等. 復發轉移食管癌患者的預后因素分析.中華腫瘤雜志, 2015, 37(2): 143-147.
13. 梅靜峰, 秦叔逵, 錢軍, 等. 多西他賽聯合順鉑治療復發性中晚期食管癌賁門癌的臨床研究.臨床腫瘤雜志, 2013, 18(14): 272-273.
14. 葛小林, 孫新臣, 李蘇宜, 等. 低劑量多西紫杉醇對中晚期食管癌放療增敏作用的近期療效觀察.海南醫學, 2011, 19(13): 135-136.
15. Calpe S, Read M, del Carmen Sancho-Serra M, et al. Abstract C04: In vivo upregulation of bone morphogenic protein 4 (BMP4) in esophageal cancer is through tumor-stroma crosstalk. Cancer Research, 2016, 76(15 Supplement): C04.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Docetaxel injection and Capecitabine tablets combined with Oxaliplatin injection in postoperative chemotherapy for esophageal cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content